In today’s briefing:
- China Healthcare Weekly (Jun.23) – National TCM VBP Results, CDE Changes Game Rule, Hua Medicine
- Thonburi Healthcare Group (THG TB): Improving Core Operation and Future Expansion to Drive Growth
![](http://www.smartkarma.com/assets/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif)
China Healthcare Weekly (Jun.23) – National TCM VBP Results, CDE Changes Game Rule, Hua Medicine
- The results of National TCM VBP were released, with average price reduction of 49.36%, involving multiple large varieties with sales over RMB1 billion and exclusive products from many listed companies.
- CDE will move closer to the FDA’s standard for approving new drugs. So, pharmaceutical companies need to update clinical strategies timely according to the situation, otherwise unexpected events may occur.
- We analyzed some key points about Hua Medicine Ltd (2552 HK). We think its core drug Dorzagliatin still has many uncertainties that are worth investors’ attention.
Thonburi Healthcare Group (THG TB): Improving Core Operation and Future Expansion to Drive Growth
- Thonburi Healthcare Group (THG TB) recorded 23% YoY increase in non-COVID medical services revenue in 1Q23, mainly driven by higher pay per bed and utilization of inpatient division.
- With the recovery in core healthcare services, THG expects its revenue to grow 10% YoY this year, accelerating from 6% revenue growth recorded in 2022.
- In the next 3 years, THG plans to increase 195 outpatient rooms and 419 beds and is set to spend nearly THB5 billion on capex during 2023–2025.